Chan Stephen L, Chan Sin T, Chan Eric H, He Zhe-Xi
State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology and Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Chin J Cancer. 2014 Jun;33(6):267-76. doi: 10.5732/cjc.013.10134. Epub 2014 Jan 29.
There have been many clinical trials conducted to evaluate novel systemic regimens for unresectable pancreatic cancer. However, most of the trial results were negative, and gemcitabine monotherapy has remained the standard systemic treatment for years. A number of molecular targeted agents, including those against epidermal growth factor receptor and vascular endothelial growth factor receptors, have also been tested. In recent years, there have been some breakthroughs in the deadlock: three regimens, namely gemcitabine-erlotinib, FOLFIRINOX, and gemcitabine-nab-paclitaxel, have been shown to prolong the overall survival of patients when compared with gemcitabine monotherapy. In addition, emerging data suggested that the membrane protein human equilibrative nucleotide transporter 1 is a potential biomarker with which to predict the efficacy of gemcitabine. Here we review the literature on the development of systemic agents for pancreatic cancer, discuss the current choices of treatment, and provide future directions on the development of novel agents.
已经开展了许多临床试验来评估用于不可切除胰腺癌的新型全身治疗方案。然而，大多数试验结果都是阴性的，多年来吉西他滨单药治疗一直是标准的全身治疗方法。一些分子靶向药物，包括针对表皮生长因子受体和血管内皮生长因子受体的药物，也已进行了测试。近年来，在这种僵局中取得了一些突破：三种治疗方案，即吉西他滨-厄洛替尼、FOLFIRINOX和吉西他滨-纳米白蛋白结合型紫杉醇，与吉西他滨单药治疗相比，已显示出可延长患者的总生存期。此外，新出现的数据表明，膜蛋白人平衡型核苷酸转运体1是一种潜在的生物标志物，可用于预测吉西他滨的疗效。在此，我们综述了关于胰腺癌全身治疗药物研发的文献，讨论了当前的治疗选择，并提供了新型药物研发的未来方向。
